Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
Charles E. Geyer Jr, MD
Advertisement
Articles by Charles E. Geyer Jr, MD
Advertisement
Latest Updated Articles
KATHERINE Results Back New Adjuvant Standard for HER2+ Breast CancerPublished: December 12th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
2
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
5
